Pemetrexed and its emerging role in the treatment of thoracic malignancies

Bibliography

• BRITTON M: The epidemiology of mesothelioma. &min. Oncol (2002) 29:18–25.
   Google Scholar
• PRICE B: Analysis of current trends in United States mesothelioma incidence. Ann. Epidemiol (1997) 145(3):211–218.
   Google Scholar
• PETO J, HOD GSON JT, MATTHEWS FE, JONES JR: Continuing increase in mesothelioma mortality in Britain. Lancet (1995) 345:535–539.
   PubMed Web of Science ®Google Scholar
• LEE JD, PEREZ S, WANG HJ et al: Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. Surg. Oncol (1995) 60(4):262–267.
   Web of Science ®Google Scholar
• RYAN CW, HERNDON J, VOGELZANG N: A review of chemotherapy trials for malignant mesothelioma. Chest (1998) 113(1, Suppl.):66S–73S.
   Google Scholar
• BUTCHART EG: Contemporary management of malignant pleural mesothelioma. Oncologist (1999) 4:488–500.
   PubMedGoogle Scholar
• MOSKAL TL, URSCHEL JD, ANDERSON TM et al: Malignant pleural mesothelioma: a problematic review. Surg. Oncol (1999) 7:5–12.
   Web of Science ®Google Scholar
• STERMAN DH, KAISER LR, ALBELDA SM: Advances in the treatment of malignant pleural mesothelioma. Chest (1999) 116:504–520.
   PubMed Web of Science ®Google Scholar
• COLBERT N, VANNETZEL JM, IZRAEL V et al.: A prospective study of detorubicin in malignant mesothelioma. Cancer (1985) 56:2170–2174.
   PubMed Web of Science ®Google Scholar
• LERNER HJ, SCHOENFELD DA, MARTIN A, FALKSON G, BORDEN E: Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1983) 52:1981–1985.
   Google Scholar
• SORENSEN PG, BACH F, BORK E, HANSEN HH: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat. Rep. (1985) 69:1431–1432.
   PubMedGoogle Scholar
• CHAHINIAN AP, ANTMAN K, GOUTSOU M et al: Randomized Phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.' Clin. Oncol (1993) 11:1559–1565.
   Web of Science ®Google Scholar
• BYRNE MJ, DAVIDSON JA, MUSK AW et al.: Cisplatin and gemcitabine treatment for malignant pleural mesothelioma: a Phase II study." Clin. Oncol (1999) 17(1):25–30.
   Google Scholar
• ZIDAR BL, GREEN S, PIERCE HI et al: A Phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest. New Drugs (1988) 6(3):223–226.
   PubMed Web of Science ®Google Scholar
• SOLHEIM OP, SAETER G, FINNANGER AM et al.: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A Phase II study. Br. Cancer (1992) 65(6):956–960.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, BELANI CP, HERNDON JE 2nd, VOGELZANG NJ, SUZUKI Y, GREEN MR: Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential Phase II trials by the cancer and leukemia group B. Cancer (1999) 86:1985–1991.
   Google Scholar
• BAAS P: Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. &min. °flea (2002) 29:62–69.
   Google Scholar
• •Review of chemotherapy regimens evaluated for the treatment of MPM.
   Google Scholar
• ONG ST, VOGELZANG NJ: Chemotherapy in malignant pleural mesothelioma: a review. Clin. °flea (1996) 14:1007–1017.
   Google Scholar
• MINTZER DM, KELSEN D, FRIMMER D, HEELAN R, GRALLA R: Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. (1985) 69:711–712.
   PubMedGoogle Scholar
• PLANTING AS, SCHELLENS JH, GOEY SH et al.: Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann. °flea (1994) 5:373–374.
   Google Scholar
• KINDLER HL, MILLARD F, HERNDON JE 2nd, VOGELZANG NJ, SUZUKI Y, GREEN MR: Gemcitabine for malignant mesothelioma: A Phase II trial by the Cancer and Leukemia Group B. Lung Cancer (2001) 31:311–317.
   PubMed Web of Science ®Google Scholar
• VAN MEERBEECK JP, BAAS P, DEBRUYNE C et al.: A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer (1999) 85(12):2577–2582.
   PubMed Web of Science ®Google Scholar
• BISCHOFF HG, MANGEGOLD C, KNOPP M et al.: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc. Am. Soc. Clin. Oncol (1998) 17:464a (Abstract).
   Google Scholar
• NOWAK AK, BYRNE MJ, WILLIAMSON R et al.: A multicentre Phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br. Cancer (2002) 87:491–496.
   Web of Science ®Google Scholar
• VAN HAARST JM, BAAS P, MANEGOLD CH et al: Multicentre Phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br. Cancer (2002) 86:342–345.
   Web of Science ®Google Scholar
• FIZAZI K, DOUBRE T, LE CHEVALIER T et al.: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a Phase II study. " Clin. Oncol (2003) 21:349–354.
   Google Scholar
• NOVELLO S, LE CHEVALIER T: Use of chemo-radiotherapy in locally advanced non-small cell lung cancer. Ear: J. Cancer (2002) 38:292–299.
   PubMed Web of Science ®Google Scholar
• RAPP E, PATER JL, WILLAN A et al.: Chemotherapy can prolong survival in patients with advanced non-small- cell lung cancer-report of a Canadian multicenter randomized trial. J. Clin. °flea (1988) 6:633–641.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• BUNN PA: Chemotherapy for advanced non-small-cell lung cancer who, what, when, why? I Clin. Oncol (2002) 20(18s, Suppl.):23s–33s.
   Google Scholar
• WATERS JS, O'BRIEN ME: The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br. J. Cancer (2002) 87:481–490.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. I Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• •A large randomised study evaluating four common platinum-based chemotherapy regimens for the treatment of advanced NSCLC.
   Google Scholar
• KELLY K, CROWLEY J, BUNN PA Jr et al.: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol (2001) 19:3210–3218.
   Google Scholar
• SCAGLIOTTI G, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.' Clin. Oncol (2002) 20:4285–4291.
   Web of Science ®Google Scholar
• NATALIE R, ZARETSKY SL: ZD1839 (Iressal: What's in it for the patient. Oncologist (2002) 7\(Suppl. 4):25–30.
   Google Scholar
• WILKINSON E: Surprise Phase III failure for ZD1839. Lancet °flea (2002) 3:583.
   PubMed Web of Science ®Google Scholar
• ALLEGRA CJ: Antifolates: the next millennium. Semin. Oncol (1999) 26(2, Suppl. 6):1–2.
   Google Scholar
• CALVERT H, BUNN PA: Future directions in the development of pemetrexed. Semin. Oncol (2002) 29(2, Suppl. 5):54–61.
   Google Scholar
• TAYLOR EC, PATEL HH: Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n {4 (2 (2 amino 4(3h)-oxo-7h-pyrrolo(2,3- d)pyrimidin-5-yflethyl)benz oy11-1-glutamic acid (LY231514). Tetrahedron Lett. (1992) 48(37):8089–8100.
   Web of Science ®Google Scholar
• HANAUSKE A-R, CHEN V, PAOLETTI P, NIYIKIZA C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist (2001) 6:363–373.
   PubMed Web of Science ®Google Scholar
• GOLDMAN DI, ZHAO R: Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin. Oncol 29(6, Suppl. 18):3–17.
   Google Scholar
• SHIH C, MENDELSOHN LG, CHEN VJ, SCHULTZ RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv. Enzyme Regal (1998) 38:135–152.
   PubMedGoogle Scholar
• MENDELSOHN LG, SHIH C, CHEN VJ, HABECK LL, GATES SB, SHACKELFORD KA: Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol (1999) 26(2, Suppl. 6):42–47.
   Google Scholar
• SCHULTZ RM, PATEL VF, WORZALLA JF, SHIH CA: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anti-Cancer Res. (1999) 19(1):437–443.
   PubMedGoogle Scholar
• VAN DER WILT CL, KUIPER CM, PETERS GJ: Combination studies of antifolates with 5-fluoroucil in colon cancer cell lines. Oncol Res. (1999) 11(8):383–391.
   PubMed Web of Science ®Google Scholar
• BACKUS HHJ, PINEDO HM, WOUTERS D et al.: Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res. (2000) 12(5):231–239.
   PubMed Web of Science ®Google Scholar
• WORZALLA JF, SHIH C, SCHULTZ RM: Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anti-Cancer Res. (1998) 18(5A):3235–3239.
   Google Scholar
• BRITTEN CD, IZBICKA E, LAWRENCE R et al.: Activity of the multitargeted antifolate LY231514 (MTA) in the human tumor cloning assay. Cancer Chemother: Pharmacol (1999) 44:105–110.
   PubMed Web of Science ®Google Scholar
• SCHULTZ RM, DEMPSEY JA, TEICHER BA et al.: Interactions between the multitargeted antifolate (MTA, LY231514) and cisplatin in non-small cell lung cancer (NSCLC) cell lines. Proc. Am. Assoc. Cancer Res. (1998) 39:308 (Abstract 2103).
   Google Scholar
• SCHULTZ RM, DEMPSEY JA, KRAUS LA, SCHMID SM, CALVETE JA, LAWS AL: In vitro sequence dependence for the multitargeted antifolate (MTA, LY231514) combined with other anticancer agents. Eur. Cancer (1999) 35 (Suppl. 4):5194. (Abstract 749).
   Google Scholar
• TONKINSON JL, WORZALLA JF, TEN CH, MENDELSOHN LG: Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. (1999) 59:3671–3676.
   PubMed Web of Science ®Google Scholar
• RINALDI DA, BURRIS HA, DORR FA et al.: Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. Clin. Oncol (1995) 13(11):2842–2850.
   Web of Science ®Google Scholar
• MCDONALD AC, VASEY PA, ADAMS L et al.: A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin. Cancer Res. (1998) 4(3):605–610.
   PubMed Web of Science ®Google Scholar
• RINALDI DA, KUHN JG, BURRIS HAet al.: A Phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol (1999) 44(5):372–380.
   Google Scholar
• MCDONALD AC, VASEY PA, WALLING J et al: Clinical Phase I study, a multitargeted antifolate, administered by daily X 5 q 21 schedule. NCI EORTC Symp. New Drugs Cancer Ther: (1996) 85 (Abstract 291).
   Google Scholar
• OUELLET D, PERICLOU AP, JOHNSON RD, WOODWORTH JR, LALONDE RL: Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother: Pharmacol (2000) 46:227–234.
   PubMed Web of Science ®Google Scholar
• GRINDEY GB, ALATI T, SHIH C: Reversal of toxicity but not the antitumor activity of lometrexol by folic acid. Proc. Am. Assoc. Cancer Res. (1991) 32:324.
   Google Scholar
• ALATI T, WORZALLA JF, SHIH C et al.: Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res. (1996) 56:2331–2335.
   PubMed Web of Science ®Google Scholar
• NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Ma Cancer Ther. (2002) 1:545–552.
   PubMed Web of Science ®Google Scholar
• ••Retrospective analysis of Phase I and IIpatient data to identify markers that predict severe toxicity with pemetrexed administration.
   Google Scholar
• CELIO L, BAJETTA E, TOFFOLATTI L et al.: Phase II trial of pemetrexed disodium administered every 21 days in patients (pts) with gastric cancer: Efficacy and toxicity without and with folic acid. Ann. Oncol (2000) 11(4):65 (Abstract 284P).
   Google Scholar
• SCAGLIOTTI GV, SHIN DM, KINDLER HL et al.: A Phase II study of pemetrexed with and without folic acid and Vitamin B12 as front-line therapy in malignant pleural mesothelioma, .1 Clin. Oncol (In press).
   Google Scholar
• •Report of Phase II trial evaluating single-agent pemetrexed as a first-line treatment for MPM patients.
   Google Scholar
• THODTMANN R, DEPENBROCK H, DUMEZ H et at Clinical and pharmacokinetic Phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. I Clin. Oncol (1999) 17(10):3009–3016.
   PubMed Web of Science ®Google Scholar
• •Phase I study evaluating pemetrexed/ cisplatin combination chemotherapy in patients with MPM.
   Google Scholar
• HUGHES A, CALVERT P, AZZABI A et al.: Phase I clinical and pharmacolkinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Clin. Oncol (2002) 20:3533–3544.
   Web of Science ®Google Scholar
• •Phase I study evaluating pemetrexed/ carboplatin combination chemotherapy in patients with MPM.
   Google Scholar
• VOGELZANG NJ, RUSTHOVEN JJ, SYMANOWSKI J et al: A Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Clin. Oncol (2003) (In press).
   Google Scholar
• ••Report of a large, multinational Phase IIItrial showing that MPM patients treated with pemetrexed plus cisplatin show improved survival compared to patients treated with cisplatin alone.
   Google Scholar
• RUSTHOVEN J, EISENHAUER E, BUTTS C et al.: Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A Phase II study../. Clin. Oncol (1999) 7(4):1194–1199.
   Google Scholar
• •Report of Phase II trial evaluating single-agent pemetrexed as a first-line treatment for patients with advanced NSCLC.
   Google Scholar
• CLARKE SJ, ABRATT R, GOEDHALS L, BOYER MJ, MILLWARD MJ, ACKLAND SP: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol (2002) 13:737–741.
   PubMed Web of Science ®Google Scholar
• •Multi-centre Phase II study of single-agent pemetrexed as a first-line treatment for patients with advanced NSCLC.
   Google Scholar
• CRIPPS C, BURNELL M, JOLIVET J et al.: Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study. Ann. Oncol (1999) 10(10):1175–1179.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol (2000) 18:2095–2103.
   PubMed Web of Science ®Google Scholar
• •Randomised comparison of docetaxel versus best supportive care for pretreated patients with advanced NSCLC.
   Google Scholar
• POSTMUS PE, BUNN PA: Pemetrexed as a single agent in the therapy of advanced lung cancer. Semin. Oncol (2002) 29(2, Suppl. 5):17–22.
   Google Scholar
• MANE GOLD C, VON PAWEL J, PIRKER R, MALAYERI R, BLATTERJ, KREJCY K: Front-line treatment of advanced non-small cell lung cancer with MTA and cisplatin: A multicenter Phase II trial. Ann. Oncol (2000) 11(4):435–440.
   PubMed Web of Science ®Google Scholar
• •Report of Phase II study of pemetrexed/ cisplatin combination for the treatment of NSCLC.
   Google Scholar
• SHEPHERD FA, DANCEY J, ARNOLD A et al.: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer (2001) 92(3):595–600.
   PubMed Web of Science ®Google Scholar
• •Report of Phase II study of pemetrexed/ cisplatin combination for the treatment of NSCLC.
   Google Scholar
• ADJEI AA, ERLICHMAN C, SLOAN JA et al.: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol (2000) 18(8):1748–1757.
   PubMed Web of Science ®Google Scholar
• ETTINGER DS, MONNERAT C, KELLY K et al.: Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer: importance of survival over response. Proc. Am. Soc. Clin. Oncol (2002) 21:8 (Abstract 1243).
   Google Scholar